The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | High-dose methotrexate as CNS prophylaxis in DLBCL
Kate Cwynarski, MD, PhD, University College Hospital, London, UK, discusses data from a multicenter analysis evaluating the impact high-dose methotrexate as CNS prophylaxis in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
